Search

Displaying results 3541 - 3550 of 4598 in total
  1. Drug

    Tiaprofenic acid

    go.drugbank.com/drugs/DB01600
    Approved

    Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).

  2. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].

  3. Drug

    Arginine

    go.drugbank.com/drugs/DB00125
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is physiologically active in the L-form.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI)
  4. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.

  5. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

  6. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  7. Drug

    Trypsin

    go.drugbank.com/drugs/DB11237
    ApprovedInvestigationalVet approved

    This nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and serine-195.

  8. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

  9. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. … Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H<sup>+</sup>, K<sup>+</sup>-ATPase-mediated gastric acid secretion.

  10. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).